The age-related macular degeneration (AMD) market in the UK, US, France, Germany, Italy, Spain and Japan was forecast to grow from $7.4bn in 2021 to $27.5bn in 2031.
Growth, according to the analytics company GlobalData, was driven by the launch of longer-acting anti-vascular endothelial growth factor (anti-VEGF) therapies, an increase in the number of people with AMD and the availability of therapies for geographic atrophy (GA).
GlobalData’s latest report, Age-related macular degeneration: seven-market drug forecast and market analysis, revealed that anti-VEGF therapies will continue to remain the dominant treatment modality for AMD during the forecast period.
Sara Reci, senior analyst at GlobalData, said: “In interviews with GlobalData, key opinion leaders emphasised that the greatest unmet needs in the AMD space included the need for longer-acting anti-VEGF therapies, treatment for GA, less invasive drug formulations, early diagnosis of patients and increasing awareness of AMD, and availability or accessibility of specialists and patient wait times.’
Register now to continue reading
Thank you for visiting Optician Online. Register now to access up to 10 news and opinion articles a month.
Register
Already have an account? Sign in here